| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 04/26/2005 | US6884795 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 04/26/2005 | US6884596 A compound that is a Prolactin Releasing Peptide receptor (PrRP) agonist; determining the ability of the compound to promote wakefulness; providing a PrRP receptor antagonist and determining the ability of the compound to promote sleep |
| 04/26/2005 | CA2216810C Method for treatment of benign prostatic hypertrophy |
| 04/21/2005 | WO2005035536A1 Novel xanthone derivative, process for producing the same and pharmaceutical composition containing the same |
| 04/21/2005 | WO2005035498A1 Use of nitrogenous bicyclic compound as feeding control agent |
| 04/21/2005 | WO2005034972A2 Use of pharmaceutical compositions containing evening primrose oil for the treatment of xerostomia |
| 04/21/2005 | WO2005034942A1 Animal feed composition |
| 04/21/2005 | WO2005034928A1 Rapid dissolution formulation of a calcium receptor-active compound |
| 04/21/2005 | WO2004111019A3 Protective groups cleavable by serumal albumins |
| 04/21/2005 | WO2004060316A3 Irs modulators |
| 04/21/2005 | WO2003049673A3 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 04/21/2005 | US20050085541 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 04/21/2005 | US20050085457 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 04/21/2005 | US20050085440 Formulation |
| 04/21/2005 | US20050085421 Derived from ghrelin polypeptide, labelled with fluorochrome and cysteine; drug screening; high throughput assay |
| 04/21/2005 | US20050085412 Hydrosilation of follicle stimulating hormone; efficiency |
| 04/21/2005 | CA2541126A1 Animal feed composition |
| 04/20/2005 | EP1524269A1 Use of 8-Prenylnaringenin for hormone replacement therapy |
| 04/20/2005 | EP1523571A2 Sgk and nedd used as diagnostic and therapeutic targets |
| 04/20/2005 | EP1523325A2 Methods and compositions for treating polycystic ovary syndrome |
| 04/20/2005 | EP1523316A2 Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1089968B1 Thyroid hormone analogues and methods for their preparation |
| 04/20/2005 | CN1608079A Chemically-modified human growth hormone conjugates |
| 04/20/2005 | CN1608078A Gonadotrophins for folliculogenesis |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608067A Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1608061A Therapeutic isoquinoline compounds |
| 04/20/2005 | CN1608059A Bipyridyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608054A Therapeutic quinolone compounds with 5-HT-antagonistic properties |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607959A Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| 04/20/2005 | CN1607954A Pregnane steroids for use in the treatment of cns dysfunction |
| 04/20/2005 | CN1607944A Pre-formulation for the tabletting of natural mixtures of conjugated estrogens |
| 04/20/2005 | CN1607943A Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| 04/20/2005 | CN1197541C Two chamber cartridge for atomizers |
| 04/19/2005 | US6881730 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 04/19/2005 | US6881728 14-β, 17-α-hydroxymethylandrostane derivatives as androgens |
| 04/16/2005 | CA2480199A1 Fp-ghrelin |
| 04/14/2005 | WO2005033700A1 Method of screening insulin resistance-improving agent |
| 04/14/2005 | WO2005033126A1 Cell surface marker |
| 04/14/2005 | WO2005033123A1 Stable vitamin b6 derivative |
| 04/14/2005 | WO2005032590A1 Remedy for diabetes |
| 04/14/2005 | WO2005032514A1 Transdermal pharmaceutical composition |
| 04/14/2005 | WO2005012347A3 Novel insulin derivatives |
| 04/14/2005 | WO2005002602A3 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 04/14/2005 | WO2005000325A3 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 04/14/2005 | WO2004110408A3 Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | US20050080266 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 04/14/2005 | US20050080120 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body |
| 04/14/2005 | US20050080117 Substituted benzoxazoles as estrogenic agents |
| 04/14/2005 | US20050080099 Methods and kits for treating depression or preventing deterioration of cognitive function |
| 04/14/2005 | US20050080065 corticosteroid with anti-inflammatory activity |
| 04/14/2005 | US20050080060 Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain |
| 04/14/2005 | US20050080057 reducing weight in mammals; Substituted with a thio, sulfoxy or sulfonyl group eg 5-Chloro-2-methylsulfonylindan-1-ol, 5-Chloro-2-(propane-2-sulfonyl)indan-1-ol, 5-Chloro-2-ethanesulfonylindan-1-ol |
| 04/14/2005 | US20050080010 Suppression of immune response via inhibition of cathepsin S |
| 04/14/2005 | CA2544574A1 Stable vitamin b6 derivative |
| 04/14/2005 | CA2541018A1 Human prostate cancer cell factor(s) that induce stem cell commitment and osteogenesis |
| 04/14/2005 | CA2540741A1 Agent for treating diabetes |
| 04/13/2005 | EP1522543A1 Use Steroid sulphatase inhibitors for the manufacture of a medicament for the treatment of an oestrogen dependent tumour |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521822A2 Protein modification and maintenance molecules |
| 04/13/2005 | EP1521764A2 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/13/2005 | EP1521733A1 Modulators of the glucocorticoid receptor |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 04/13/2005 | EP1294739B1 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity |
| 04/13/2005 | EP1289955B1 Piperidines for use as orexin receptor antagonists |
| 04/13/2005 | EP1212052B1 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 04/13/2005 | CN1606553A Oxytocin agonistenoxytocin agonisten |
| 04/13/2005 | CN1606551A Substituted 2-phenyl benzofurans as estrogenic agents |
| 04/13/2005 | CN1196708C Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols |
| 04/12/2005 | US6878750 Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents |
| 04/12/2005 | US6878726 For therapy and prophylaxis inflammation, other inflammation associated disorders, such as arthritis, neurodegeneration and colon cancer, in mammals, dogs, cats or livestock animals |
| 04/12/2005 | US6878690 Compounds and methods |
| 04/12/2005 | US6878529 Compounds for the treatment of sexual dysfunction |
| 04/12/2005 | CA2385854C Formulation for menopausal women |
| 04/07/2005 | WO2005030213A1 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo |
| 04/07/2005 | WO2005012269A8 Novel azole compound |
| 04/07/2005 | WO2004112511A3 Supplement for restoring growth hormone levels |
| 04/07/2005 | WO2004006847A3 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 04/07/2005 | US20050075397 Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof |
| 04/07/2005 | US20050075396 Modulation of type 2 diabetes and drug delivery |
| 04/07/2005 | US20050075339 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/07/2005 | US20050075338 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075328 Such as (2'-methoxy-[1,1'-biphenyl]-4-yl)-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)methanone; for treatment of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or hemophilia |
| 04/07/2005 | US20050075322 Androgenic 7-substituted 11-halogen steroids |
| 04/07/2005 | US20050075288 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/07/2005 | US20050075269 Substituted benzofuran-2-carboxamides derivatives |
| 04/07/2005 | US20050074841 DNAs encoding mammalian histamine receptor of the H4 subtype |
| 04/07/2005 | US20050074770 Cloned mammalian histamine H4 receptor that couples to G-protein; for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | CA2540104A1 Water soluble nanoparticles comprising inclusion complexes |
| 04/06/2005 | EP1519915A2 Tricyclic steroid hormone nuclear receptor modulators |
| 04/06/2005 | EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 04/06/2005 | EP1100509B1 Use of biogenic estrogen sulfamates for hormone replacement therapy |